Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives

The clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and al...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xin, Li, Ziping, Liu, Hangkuan, Li, Yongle, Zhao, Dong, Yang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129148/
https://www.ncbi.nlm.nih.gov/pubmed/36806078
http://dx.doi.org/10.1097/CM9.0000000000002057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129148/
https://www.ncbi.nlm.nih.gov/pubmed/36806078
http://dx.doi.org/10.1097/CM9.0000000000002057

Ejemplares similares